Survivorship – Cutaneous Melanoma

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

ELIGIBILITY

CONCURRENT COMPONENTS OF VISIT

SURVEILLANCE

MONITORING FOR LATE EFFECTS

RISK REDUCTION/EARLY DETECTION

PSYCHOSOCIAL FUNCTIONING

DISPOSITION

Positive findings?

Return to primary treating physician

No

Continue survivorship monitoring

NED = No Evidence of Disease

1All patients with multiple melanomas should be transitioned based on number of disease free years with regards to the highest stage melanoma or number of disease free years for the last treated melanoma whichever is longer.

Stage 0, NED at 6 months1

Stage IA, NED at 2 years1

Stage IB – II, NED at 5 years1

Stage III – IV, disease free interval of 5 years1

Years 1 and up:
- History and physical examination to include complete skin and lymph node basin survey
- Reinforce skin inspection patient education

Years 3 and up:
- History and physical examination to include complete skin and lymph node basin survey
- Reinforce skin inspection patient education

Years 6 and up:
- History and physical examination to include complete skin and lymph node basin survey
- Reinforce skin inspection patient education

Years 6 and up:
- History and physical examination to include complete skin and lymph node basin survey
- Chest x-ray as clinically indicated
- LDH for staging if stage IV recurrence is detected
- Interval CT chest, abdomen, and pelvis or PET-CT as clinically indicated
- MRI brain as clinically indicated
Melanoma post-treatment and NED

**MONITORING FOR LATE EFFECTS**
- Assess for:
  - Lymphedema (upper and lower limbs)
  - Range of motion
  - Autoimmune manifestations of adjuvant immunotherapy

**RISK REDUCTION/EARLY DETECTION**
- Patient education, counseling, and screening:
  - Lifestyle risk assessment
  - Cancer screening
  - HPV vaccination as clinically indicated (see HPV Vaccination Algorithm)
  - Screening for Hepatitis B and C as clinically indicated (see Hepatitis Screening and Management – HBV and HCV Algorithm)
  - Cardiovascular risk assessment
  - Vaccinations as appropriate
  - New masses and other symptoms (e.g., bone pain) should be evaluated as clinically indicated

**PSYCHOSOCIAL FUNCTIONING**
- Assess for:
  - Distress management (see Distress Screening and Psychosocial Management Algorithm)
  - Body image
  - Financial stressors
  - Social support

---

**ELIGIBILITY**

**CONCURRENT COMPONENTS OF VISIT**

**DISPOSITION**

Refer or consult as indicated

---

**NED = No Evidence of Disease**

1 See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

2 Includes breast, cervical (if appropriate), colorectal, liver, lung, pancreatic, prostate, and skin cancer screening

3 Consider use of Vanderbilt’s ABCDE’s approach to cardiovascular health

4 Based on Centers for Disease Control and Prevention (CDC) guidelines

---

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.
Survivorship – Cutaneous Melanoma

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS


This survivorship algorithm is based on majority expert opinion of the Melanoma Survivorship work group at the University of Texas MD Anderson Cancer Center.

It was developed using a multidisciplinary approach that included input from the following:

Olga N. Fleckenstein*
Jeffrey E. Gershenwald, MD†
Paula Lewis-Patterson, DNP, RN, NEA-BC
Jeffrey N. Myers, MD
Kristen Pytynia, MD
E. Lane Read, PA-C
Merrick Ross, MD
Erich M. Sturgis, MD
Shirlene Tabao, MSN, RN, OCN*
Hussein Tawbi, MD, PhD
Randal S. Weber, MD
Mark Zafereo, MD

† Core Development Lead
* Clinical Effectiveness Development Team